Our People
Vanessa Park-Thompson

Vanessa Park-Thompson

212-430-2691
vpark-thompson@fenwick.com
Partner
Litigation
Office

New York

Vanessa
Park-Thompson

Vanessa
Park-Thompson

Vanessa
Park-Thompson

Partner
Litigation
Office

New York

Industries
Education & Admissions

J.D., University of Toronto

B.Sc., Neuroscience
McGill University

Admitted to practice in New York

Admitted to practice before the U.S. Tax Court, the U.S. Court of Appeals for the Federal Circuit, and the U.S. District Courts for the Eastern and Southern Districts of New York

Member of the Law Society of Ontario

Vanessa supports innovative life sciences and high-tech companies through their most complex and contentious disputes, including those involving biologics, gene therapy, peptides, complex nanomolecules, and software. In heated conflicts between competitor companies, contentious tax matters in which hundreds of millions of dollars or more are at stake, and licensing disputes with former business partners, Vanessa successfully navigates high-pressure controversies to achieve favorable outcomes for her clients. She also counsels clients on sophisticated global intellectual property strategies and risk mitigation, including transactional matters related to patent rights and portfolio analysis.

Vanessa’s professional journey has been punctuated with career-defining milestones. Beginning her career in Canada, she represented an innovative pharmaceutical company in several of the country's first biologics and biosimilars patent trials. More recent achievements include defending the validity of patents covering the blockbuster medication Ozempic® and taking to trial a high-profile and precedent-setting Tax Court case involving tax deductions for online software.

Vanessa is heavily involved in firm DEI and recruiting efforts. She currently serves as the Fenwick Women’s Caucus representative for the New York office and has previously served on the firm’s Hiring Committee, Alumni Committee, and Recruiting Committee.

Vanessa is committed to providing pro bono legal services, and proudly partners with her corporate clients to coordinate legal aid clinics on initiatives such as immigration assistance.

Read more

  • Representing Novo Nordisk in pending Hatch-Waxman patent infringement lawsuits brought against six generic pharmaceutical manufacturers concerning Novo Nordisk’s blockbuster type 2 diabetes therapy and best-selling product Ozempic®
  • Representing a global software company in precedent-setting U.S. Tax Court litigation
  • Guiding both established multinational and nascent startup companies through complex and contentious IRS audits and other pre-litigation proceedings against the IRS
  • Advised innovative drug company on patent and commercial strategies and risk mitigation regarding various gene therapy products
  • Obtained highly favorable settlement for Pharmacosmos A/S and Pharmacosmos Therapeutics in patent litigation brought by a competitor in relation to Pharmacosmos’ newly launched iron deficiency anemia treatment Monoferric®
  • Represented Pfizer in class action lawsuit concerning the drug Celebrex® arising under federal and state antitrust and unfair competition laws
  • Represented Almirall in Hatch-Waxman patent litigation involving the acne treatment drug Aczone® and successfully resolved the claims on the eve of trial
  • Defended Nutanix, Nexon America, Nexon Korea, and Nexon Co. against separate infringement lawsuits brought by non-practicing entity Uniloc related to automated license and distribution management of software in enterprises

  • Representing Novo Nordisk in pending Hatch-Waxman patent infringement lawsuits brought against six generic pharmaceutical manufacturers concerning Novo Nordisk’s blockbuster type 2 diabetes therapy and best-selling product Ozempic®
  • Representing a global software company in precedent-setting U.S. Tax Court litigation
  • Guiding both established multinational and nascent startup companies through complex and contentious IRS audits and other pre-litigation proceedings against the IRS
  • Advised innovative drug company on patent and commercial strategies and risk mitigation regarding various gene therapy products
  • Obtained highly favorable settlement for Pharmacosmos A/S and Pharmacosmos Therapeutics in patent litigation brought by a competitor in relation to Pharmacosmos’ newly launched iron deficiency anemia treatment Monoferric®
  • Represented Pfizer in class action lawsuit concerning the drug Celebrex® arising under federal and state antitrust and unfair competition laws
  • Represented Almirall in Hatch-Waxman patent litigation involving the acne treatment drug Aczone® and successfully resolved the claims on the eve of trial
  • Defended Nutanix, Nexon America, Nexon Korea, and Nexon Co. against separate infringement lawsuits brought by non-practicing entity Uniloc related to automated license and distribution management of software in enterprises

Recognition Recognition Recognition

Recognition Recognition Recognition

Recognition
Super Lawyers

2022, 2023

New York Rising Star, Intellectual Property Litigation

Recognition
Super Lawyers

2022, 2023

New York Rising Star, Intellectual Property Litigation